Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2135 : NIH:OVCAR-3  update : 2022/09/01
CommentHuman cell line derived from adenocarcinoma of ovary. TKG0602 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Hamilton T.C.
Year of deposit 2005
Original cell TKG0602
Animal human < Mammals
Genus Homo
Species sapiens
Tissue ovary, ascites meta
Disease name progressive adenocarcinoma of ovary
Metastastatic ability Yes
Metastatsd tissue ascites
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0602)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_0465
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.02% EDTA-PBS or 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 9
User's Publication 16


To topTop
Reference
5109  Chien CH1, Wang FF, Hamilton TC.  Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells.  Mol Cell Endocrinol  1994  99(1):11-9  PubMed ID: 8187952   DOI: 10.1016/0303-7207(94)90140-6
5108  Kanemoto T1, Martin GR, Hamilton TC, Fridman R.  Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel).  Invasion Metastasis  1991  11(2):84-92  PubMed ID: 1917387  
5107  Nash JD1, Ozols RF, Smyth JF, Hamilton TC.  Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.  Obstet Gynecol  1989  73(6):1009-16  PubMed ID: 2542854   DOI: 10.1097/00006250-198906000-00021
5104  Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.  Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.  Biochem Pharmacol  1987  36(1):147-53  PubMed ID: 3801051   DOI: 10.1016/0006-2952(87)90392-3
5105  FitzGerald DJ, Bjorn MJ, Ferris RJ, Winkelhake JL, Frankel AE, Hamilton TC, Ozols RF, Willingham MC, Pastan I.  Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.  Cancer Res  1987  47(5):1407-10  PubMed ID: 3493065  
5106  Holt JA, Waggoner SE, Lee EY, Hubby MM, Hamilton TC.  Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin.  Gynecol Oncol  1987  27(3):282-93  PubMed ID: 3476351  
5102  Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF.  Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.  Cancer Res  1984  44(11):5427-31  PubMed ID: 6488194  
5103  Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.  Cancer Res  1984  44(11):5286-90  PubMed ID: 6333272  
5101  Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.  Cancer Res  1983  43(11):5379-89  PubMed ID: 6604576  

To topTop
User's Publication
20521  Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R.  The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.  Commun Biol  2022  5(1):39  PubMed ID: 35017636   DOI: 10.1038/s42003-021-02992-4
20745  Kobayashi T, Mitsuhashi A, Hongying P, Shioya M, Kojima K, Nishikimi K, Yahiro K, Shozu M.  Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis.  Sci Rep  2022  12(1):11123  PubMed ID: 35778597   DOI: 10.1038/s41598-022-15348-7
20938  Kanda M, Serada S, Hiramatsu K, Funauchi M, Obata K, Nakagawa S, Ohkawara T, Murata O, Fujimoto M, Chiwaki F, Sasaki H, Ueda Y, Kimura T, Naka T.  Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.  Neoplasia  2022  35:100853  PubMed ID: 36413881   DOI: 10.1016/j.neo.2022.100853
9937  Ryosuke Koyama, Yui Kano, Kaori Kikushima, Ayaka Mizutani, Yuta Soeda, Kazuki Miura, Takako Hirano, Toshiyuki Nishio, Wataru Hakamata  A Novel Golgi Mannosidase Inhibitor: Molecular Design, Synthesis, Enzyme Inhibition, and Inhibition of Spheroid Formation  Bioorg Med Chem  2020  28(11):115492  PubMed ID: 32291147   DOI: 10.1016/j.bmc.2020.115492
20125  Iwahashi N, Ikezaki M, Nishikawa T, Namba N, Ohgita T, Saito H, Ihara Y, Shimanouchi T, Ino K, Uchimura K, Nishitsuji K.  Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.  Proc Natl Acad Sci U S A  2020  117(52):33225-33234  PubMed ID: 33318190   DOI: 10.1073/pnas.2009931117
14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677   DOI: 10.1007/s00705-019-04474-9
12529  Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y.  ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer  Cancer Sci  2019  110(3):1105-1116  PubMed ID: 30633424   DOI: 10.1111/cas.13936
9868  Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H.  Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.  Oncol Lett  2016  12:4720-4726  PubMed ID: 28105179   DOI: 10.3892/ol.2016.5239
9899  Saito KI, Inoue Y, Ikegami Y, Nanbo I, Onozuka M, Sano K, Yoshida H, Sakamoto T, Tatebayashi E, Fujita KI, Sasaki Y, Kitazawa T.  Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.  Anticancer Res.  2016  36:5957-5963  PubMed ID: 27793921   DOI: 10.21873/anticanres.11183
15130  Asanuma D, Sakabe M, Kamiya M, Yamamoto K, Hiratake J, Ogawa M, Kosaka N, Choyke PL, Nagano T, Kobayashi H, Urano Y.  Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo  Nat Commun  2015  6:6463  PubMed ID: 25765713   DOI: 10.1038/ncomms7463
13706  Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K.  Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells  PLoS One  2014  9(11):e112438  PubMed ID: 25375122   DOI: 10.1371/journal.pone.0112438
9669  Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa  Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells  Int J Oncol  2013  43(1):63-71  PubMed ID: 23670532   DOI: 10.3892/ijo.2013.1935
14401  Yamaguchi Y, Deng D, Sato Y, Hou YT, Watanabe R, Sasaki K, Kawabe M, Hirano E, Morinaga T.  Silicate fiber-based 3D cell culture system for anticancer drug screening  Anticancer Res  2013  33(12):5301-9  PubMed ID: 24324063  
7849  Yoshida H, Sumi T, Zhi X, Yasui T, Honda K, Ishiko O.  Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.  Anticancer Res.  2011  31:1271-7  PubMed ID: 21508375  
7910  Masuishi Y, Arakawa N, Kawasaki H, Miyagi E, Hirahara F, Hirano H.  Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma.  FEBS J.  2011  278:1470-83  PubMed ID: 21348943   DOI: 10.1111/j.1742-4658.2011.08059.x
8169  Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, Inoue M.  Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.  Cancer Sci.  2010  101:2171-8  PubMed ID: 20678156   DOI: 10.1111/j.1349-7006.2010.01670.x



Back Back Return Top Page